Pablo Umana

Schlieren, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 106 publications

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal: Journal for immunotherapy of cancer
Published: May 19, 2026

FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters.

FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters.

Journal: Journal for immunotherapy of cancer
Published: May 14, 2026

Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients.

Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients.

Journal: Frontiers in immunology
Published: March 31, 2026

Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

Journal: Cancer research communications
Published: March 18, 2026

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Journal: Nature medicine
Published: January 17, 2026

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.

Journal: mAbs
Published: December 16, 2025

FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors.

FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 23, 2025

PD1-IL2v expands and induces effector CD8+ TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model.

PD1-IL2v expands and induces effector CD8+ TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model.

Journal: Journal of experimental & clinical cancer research : CR
Published: October 22, 2025

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.

Journal: Antibodies (Basel, Switzerland)
Published: September 27, 2025

PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer.

PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer.

Journal: Science translational medicine
Published: September 17, 2025

Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies.

Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies.

Journal: Oncoimmunology
Published: September 02, 2025

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Journal: Blood advances
Published: April 21, 2025
Showing 1-12 of 106

Last Updated: 09/26/2026